Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
J Cutan Pathol ; 48(9): 1124-1132, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33675561

ABSTRACT

BACKGROUNDS: Follicular mycosis fungoides (FMFs) is a distinct form of T-cell lymphoma whose course is considered aggressive. METHODS: A retrospective study with long-term follow-up of 20 patients diagnosed with spiky/keratosis-pilaris-like FMF between 2008 and 2017 was conducted. RESULTS: Twelve males and eight females were identified, with a mean age at first diagnosis of 59 years (range 42-86). Hyperkeratotic follicular papules were the sole clinical finding in 16 of 20 patients. A diagnostic delay between first symptom development and initial diagnosis was frequent (mean 42 months). The head/neck region was concurrently affected only in two patients. Disease stage at diagnosis was IA in two patients (10%) and IB in 18 (90%). Five patients had almost complete lesion regression, whilst there was only a slight improvement, without regression in 14. Two patients developed infiltrated papules, comedones, and small cysts during follow-up. Only one patient progressed to tumor stage (IIB) five years after the first diagnosis. The mean follow-up was seven years (range: 12-180 months). None of them died of cutaneous lymphoma. CONCLUSIONS: FMF presenting with only spiky/keratosis-pilaris-like lesions have an excellent prognosis at medium-term follow-up. Early recognition of patients with this peculiar FMF presentation might lead to identifying prognostic factors.


Subject(s)
Abnormalities, Multiple/diagnosis , Darier Disease/diagnosis , Eyebrows/abnormalities , Mycosis Fungoides/diagnosis , Skin Neoplasms/pathology , Abnormalities, Multiple/pathology , Adult , Aged , Aged, 80 and over , Darier Disease/pathology , Delayed Diagnosis , Disease Progression , Eyebrows/pathology , Female , Follow-Up Studies , Humans , Lymphoma, T-Cell/pathology , Male , Middle Aged , Mycosis Fungoides/pathology , Neoplasm Staging/methods , Prognosis , Retrospective Studies
2.
Dermatol Ther ; 33(6): e14516, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33169500

ABSTRACT

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there has been an open debate on the impact of biological drugs used in the treatment of psoriasis. To define whether patients under treatment with biologics suffer from increased morbidity and mortality from COVID-19, compared to psoriatic patients treated only with topical drugs, we designed an observational monocentric prevalence study recording the personal and clinical data of psoriatic patients, with focus on the presentation of signs and symptoms related to COVID-19 in the period of time ranging from 1 January 2020 to 31 May 2020. A total of 180 patients were enrolled into two groups: 100 patients in the topical therapy group and 80 patients in the biological therapy group. No statistically significant difference was found between the groups regarding the prevalence of COVID-19 infection and symptoms at a bivariable analysis with adjustment for confounders. In conclusion, psoriatic patients under treatment with biologics do not seem to be more susceptible to COVID-19 compared to other psoriatic patients and we suggest not interrupting treatment with biological drugs, even in areas suffering from active outbreaks of the disease.


Subject(s)
Biological Products/administration & dosage , COVID-19/epidemiology , Dermatologic Agents/administration & dosage , Immunosuppressive Agents/administration & dosage , Psoriasis/drug therapy , Adult , Aged , Biological Products/adverse effects , COVID-19/immunology , Dermatologic Agents/adverse effects , Drug Administration Schedule , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Italy/epidemiology , Male , Middle Aged , Prevalence , Prospective Studies , Psoriasis/epidemiology , Psoriasis/immunology , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome
4.
J Am Acad Dermatol ; 81(2): 527-533, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30617027

ABSTRACT

BACKGROUND: It is general opinion that histopathology is nonspecific and of little value in diagnosing erosive pustular dermatosis of the scalp (EPDS). OBJECTIVES: Clinicopathologic correlation of erosive pustular dermatosis of the scalp. METHODS: We reviewed the clinical and pathologic records of patients with a clinicopathologic diagnosis of EPDS between 2011 and 2016 at the Dermatopathology Unit of Turin University. RESULTS: Thirty elderly patients with EPDS were identified (22 men and 8 women). Androgenetic alopecia was present in 19 of 30 patients. Triggering factors included mechanical trauma in 10 of 30 cases, surgical procedures in 4 of 30 cases, and herpes zoster in 1 of 30 cases. Three patients were affected by autoimmune disorders. The vertex was the most common location. Disease presentation varied markedly from tiny, erosive, scaly lesions to crusted and hemorrhagic plaques, mimicking pustular pyoderma gangrenosum. The pathologic changes differed according to lesion type and disease duration. Interestingly, a spongiotic and suppurative infundibulo-folliculitis was observed in 8 of 30 cases. LIMITATIONS: This was a retrospective study. CONCLUSIONS: We believe that the primary lesion of erosive pustular dermatosis of the scalp is a spongiotic, pustular superficial folliculitis. The clinicopathologic similarities with other neutrophilic dermatoses, such as pustular pyoderma gangrenosum, suggest this condition should be included in this spectrum, where pathergy plays a pathogenetic role.


Subject(s)
Folliculitis/pathology , Neutrophils/pathology , Scalp Dermatoses/diagnosis , Scalp Dermatoses/pathology , Aged , Aged, 80 and over , Alopecia/pathology , Diagnostic Errors , Female , Folliculitis/etiology , Humans , Male , Middle Aged , Scalp Dermatoses/etiology , Time Factors
5.
J Cutan Pathol ; 46(11): 844-851, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31161673

ABSTRACT

Herein, we describe a patient with immunoglobulin G (IgG)-lambda smoldering multiple myeloma with translocation t(4:14) who developed widespread ulcerative horny-like spicules, heralding rapid progression to overt myeloma requiring aggressive chemotherapy and autologous stem cell transplantation. The serum abnormal immunoglobulin in the blood was cryoglobulin, which typically precipitates in the tissues at low temperatures causing inflammation and tissue damage. Histopathological changes, observed in lesions at different evolutionary stages, evidenced columns of horny-like eosinophilic homogeneous material, immunoreactive for IgG lambda, protruding from the dilated and/or distorted follicular openings or acrosyringia and small vessel thrombotic vasculopathy and vasculitis in concert with an inflammatory neutrophilic and lymphocytic reaction. Biochemical investigations on material from a spicule and ulcero-necrotic lesion revealed cryoprecipitates containing IgG-lambda with electrophoretic characteristics identical to those of the serum dysprotein. Our findings suggest that the formation of spicules and development of ulcerative lesions are a part of the same clinical spectrum where the cold-dependent precipitation of the immunogenic dysprotein, both in the skin vessels and hair follicle infundibula, play a major pathogenetic role. Whether this highly characteristic paraneoplastic dermatosis can identify patients with high-risk cytogenetic abnormalities and be incorporated into prognostic models, applicable early on in the course of myeloma, warrants further investigation.


Subject(s)
Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 4/genetics , Multiple Myeloma , Skin Neoplasms , Smoldering Multiple Myeloma , Translocation, Genetic , Autografts , Hair Follicle/metabolism , Hair Follicle/pathology , Hematopoietic Stem Cell Transplantation , Humans , Male , Middle Aged , Multiple Myeloma/genetics , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Multiple Myeloma/therapy , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Smoldering Multiple Myeloma/genetics , Smoldering Multiple Myeloma/metabolism , Smoldering Multiple Myeloma/pathology , Smoldering Multiple Myeloma/therapy , Transplantation, Autologous
6.
Dermatol Ther ; 32(2): e12821, 2019 03.
Article in English | MEDLINE | ID: mdl-30638288

ABSTRACT

We report the case of a female patient who developed a firm, wooden-like, nonpitting edema of the left lower leg after a dermo-hypodermitis. The clinical picture was accompanied by intense pain, strongly impacting the patient's quality of life. A soft-tissue ultrasound demonstrated several millimetric hyperechoic linear lesions whose histopathological examination was conclusive for panniculitis ossificans. A conservative medical management with compression stockings associated with pentoxifylline 800 mg/day was prescribed with improvement of the edema and, in particular, a good pain control. To date, after a 2-year therapy with pentoxifylline, the leg wooden-like edema has substantially improved, despite the persistence of the well-known foci of ossification, and the pain has resolved, conditioning a substantial improvement of the patient's quality of life. No side effect has been observed during the routine follow up. Although there is no unanimous opinion in the literature about the effect of pentoxifylline on bone formation and osteogenic differentiation, pentoxifylline treatment proved to be beneficial in our patient both for the heterotopic ossification process and the pain control. We collected some of the data in literature about pentoxifylline effects and advanced some hypotheses to explain our results. Finally, we suggest that an anti-inflammatory and vasodilators drug such as pentoxifylline could be a possible alternative in heterotopic ossification disorders.


Subject(s)
Erysipelas/complications , Panniculitis/drug therapy , Pentoxifylline/administration & dosage , Vasodilator Agents/administration & dosage , Aged, 80 and over , Female , Humans , Lower Extremity/diagnostic imaging , Ossification, Heterotopic/drug therapy , Panniculitis/diagnostic imaging , Panniculitis/etiology , Quality of Life , Ultrasonography
7.
Dermatol Ther ; 32(4): e12948, 2019 07.
Article in English | MEDLINE | ID: mdl-31025498

ABSTRACT

It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.


Subject(s)
Lymphoma, B-Cell/drug therapy , Pemphigus/drug therapy , Rituximab/administration & dosage , Skin Neoplasms/drug therapy , Aged, 80 and over , Antineoplastic Agents, Immunological/administration & dosage , Female , Humans , Immunologic Factors/administration & dosage , Lymphoma, B-Cell/pathology , Male , Middle Aged , Pemphigus/immunology , Skin Neoplasms/pathology , Treatment Outcome
8.
J Pediatr Hematol Oncol ; 41(1): 34-37, 2019 01.
Article in English | MEDLINE | ID: mdl-30130275

ABSTRACT

Mycosis fungoides (MF) is a rare disease and is considered the most common form of cutaneous T-cell lymphoma. Given the infrequent incidence of MF in patients under the age of 20, there are no established guidelines for the treatment of these patients; the overwhelming majority have an early-stage disease and progression to more advanced stages is very rare. This study presents the safety and effectiveness of photo-photochemotherapy as a first-line approach in the treatment of an early-stage MF even in young patients.


Subject(s)
Mycosis Fungoides/drug therapy , Photochemotherapy/methods , Adolescent , Adult , Child , Female , Humans , Male , Mycosis Fungoides/diagnosis , Mycosis Fungoides/pathology , Neoplasm Staging , Photochemotherapy/adverse effects , Retrospective Studies
9.
Pediatr Dermatol ; 35(3): 384-387, 2018 May.
Article in English | MEDLINE | ID: mdl-29582455

ABSTRACT

BACKGROUND: Cutaneous leishmaniasis has an incidence of 0.7-1.2 million cases per year and represents a growing concern in the outpatient dermatologic practice in Europe because of imported cases due to increased travel to risk areas and to immigration phenomena. When dealing with children, the treatment can be challenging because of side effects and pain of classic antimonial therapy leading to poor rates of course completion and requirement of sedation for several children. METHODS: We retrospectively studied three cases of cutaneous leishmaniasis in pediatric patients, between the ages of 3 and 6 years of age, treated with oral fluconazole. We examined the efficacy, the tolerability, the safety profile and the cosmetic result of fluconazole at a dose of 6 mg/kg/daily for 6 weeks. RESULTS: The patients had a complete resolution of their lesions with minimal scarring. No adverse effect was reported. The leishmaniasis species identified were L. major or L. tropica. CONCLUSION: Considering sides effects and the parents' and the clinician's concern for systemic treatment in the pediatric population, fluconazole represents a valid, safe and easily manageable option for Old World cutaneous leishmaniasis in pediatric outpatients caused by L. major or L. tropica.


Subject(s)
Antifungal Agents/administration & dosage , Fluconazole/administration & dosage , Leishmania/isolation & purification , Leishmaniasis, Cutaneous/drug therapy , Administration, Oral , Antifungal Agents/adverse effects , Child , Child, Preschool , Female , Fluconazole/adverse effects , Humans , Male , Retrospective Studies , Treatment Outcome
10.
J Dtsch Dermatol Ges ; 21(11): 1417-1420, 2023 11.
Article in English | MEDLINE | ID: mdl-37919045
12.
J Dtsch Dermatol Ges ; 19(10): 1521-1523, 2021 Oct.
Article in German | MEDLINE | ID: mdl-34661364
18.
J Dtsch Dermatol Ges ; 17(4): 461-463, 2019 04.
Article in German | MEDLINE | ID: mdl-30958936
19.
Dermatopathology (Basel) ; 11(1): 79-100, 2024 Feb 07.
Article in English | MEDLINE | ID: mdl-38390850

ABSTRACT

Galli-Galli disease (GGD) is a rare genodermatosis that exhibits autosomal dominant inheritance with variable penetrance. GGD typically manifests with erythematous macules, papules, and reticulate hyperpigmentation in flexural areas. A distinct atypical variant exists, which features brown macules predominantly on the trunk, lower limbs, and extremities, with a notable absence of the hallmark reticulated hyperpigmentation in flexural areas. This review includes a detailed literature search and examines cases since GGD's first description in 1982. It aims to synthesize the current knowledge on GGD, covering its etiology, clinical presentation, histopathology, diagnosis, and treatment. A significant aspect of this review is the exploration of the genetic, histopathological, and clinical parallels between GGD and Dowling-Degos disease (DDD), which is another rare autosomal dominant genodermatosis, particularly focusing on their shared mutations in the KRT5 and POGLUT1 genes. This supports the hypothesis that GGD and DDD may be different phenotypic expressions of the same pathological condition, although they have traditionally been recognized as separate entities, with suprabasal acantholysis being a distinctive feature of GGD. Lastly, this review discusses the existing treatment approaches, underscoring the absence of established guidelines and the limited effectiveness of various treatments.

20.
J Clin Med ; 13(10)2024 May 16.
Article in English | MEDLINE | ID: mdl-38792476

ABSTRACT

Background/Objectives: Eosinophilic dermatosis of hematologic malignancy (EDHM) is a rare cutaneous disorder associated with various hematologic malignancies, most commonly chronic lymphocytic leukemia. Detailed clinicopathologic studies of EDHM are lacking and the pathogenesis remains enigmatic. Initially thought to be a hypersensitivity reaction to insect stings, subsequent reports have challenged this understanding. The prognostic implications of EDHM remain unclear. Methods: A retrospective clinicopathologic study was performed on patients diagnosed with EDHM. Hematologic and dermatologic data were reviewed. Histologic specimens were re-evaluated and lesions were classified into acute/subacute, fully developed, and chronic/regressing. Results: The study included 35 patients. In 80% of these patients, EDHM was diagnosed after the hematologic disorder. Approximately 45% of the cohort experienced hematologic disease progression or relapse, while 65% required therapeutic intervention during the course of their hematologic disease. In total, 15/19 CLL patients had non-mutated IgHV, a marker of a more aggressive hematologic disease course. Dermatologic lesion morphology was heterogeneous, with most lesions occurring on exposed areas, and a significant 94% of patients demonstrated lesion seasonality. Histopathologic findings were consistent with features typically associated with insect bites. In addition, examination of lesions at different chronological stages revealed substantial similarities with Wells syndrome. Conclusions: Our findings support the potential role of insect bites in triggering EDHM in the context of adaptive immune dysfunction. EDHM may be associated with a more aggressive disease course or may be a marker of disease progression. The observed co-occurrence of features typical of Wells syndrome in EDHM patients suggests that these conditions are part of a spectrum of disorders that vary in clinical expression.

SELECTION OF CITATIONS
SEARCH DETAIL